Loading...
•
Jun 30, 2024
Phathom Q2 2024 Earnings Report
Reported second quarter 2024 financial results and provided business update.
Key Takeaways
Phathom Pharmaceuticals reported net revenues of $7.3 million for the second quarter 2024, a greater than 280% increase compared to the first quarter 2024. The company also highlighted the FDA approval of VOQUEZNA 10 mg tablets for heartburn associated with Non-Erosive GERD and the expansion of commercial coverage to over 116 million U.S. lives.
Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly report
Net revenues of $7.3 million reported for the second quarter 2024 compared to $1.9 million in the first quarter 2024, greater than a 280% increase
VOQUEZNA (vonoprazan) tablets 10mg now FDA-approved and available to treat heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (GERD) in adults – unlocking the entire GERD market of over 22 million diagnosed and annually treated patients
Expansion of commercial coverage for VOQUEZNA tablets now includes over 116 million U.S. lives, an estimated 77% of total U.S. commercial lives
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...